<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2025000100034</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.24000044</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Prevalence and burden of oral complications in breast cancer: systematic literature review]]></article-title>
<article-title xml:lang="es"><![CDATA[Prevalencia y carga de complicaciones orales en cáncer de mama: revisión sistemática de la literatura]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Espinosa]]></surname>
<given-names><![CDATA[Evelyn]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marroquín-Velásquez]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,London  ]]></institution>
<addr-line><![CDATA[London ]]></addr-line>
<country>UK</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Costa Rica Nuclear and Molecular Sciences Center for Research in Atomic]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>24</volume>
<numero>1</numero>
<fpage>34</fpage>
<lpage>47</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2025000100034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2025000100034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2025000100034&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Clinical management of breast cancer (BC) survivorship rarely involves evidence-based oral care. This review aimed to provide data on the prevalence and burden of oral complications (OC) among BC patients and to provide recommendations for optimal management of OCs in this population. The review was conducted using systematic searches in electronic databases up to July 2023 following a predefined protocol (CRD42021272130). The occurrence of at least one OC, beyond the well-known mucositis or stomatitis, was reported by 14% of close to 8,000 BC patients with an average age of 54 years. The most prevalent were periodontitis, gingivitis, ulcers, pain, tooth loss, or xerostomia. When evaluated, OCs were more prevalent in BC patients compared to controls and were mostly reported temporarily during treatment. A higher prevalence was observed from real-world data compared to interventional data. Although scarce and heterogeneous, burden data suggested that OCs negatively impact patients’ quality of life and overall costs of treatment. OCs are scarcely studied but their occurrence impacts negatively patient’s everyday lives. Standardized well-designed oral health research focusing on region-specific cost-effective management approaches is crucial for optimizing care delivery for BC survivors.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cuidado oral de supervivientes de cáncer de mama (CM) es un tema poco considerado en la práctica clínica. El objetivo de esta revisión es obtener evidencia médica sobre la prevalencia de las complicaciones orales (CO) y la carga humana y económica que estas generan en pacientes y sistemas de salud, además de presentar recomendaciones para el óptimo manejo de las CO en esta población. La revisión se realizó usando búsquedas sistemáticas en bases de datos electrónicas hasta julio de 2023, siguiendo un protocolo predefinido (CRD42021272130). La ocurrencia de al menos una CO, además de las comúnmente conocidas mucositis y estomatitis, se reportó por el 14% de cerca de 8,000 pacientes de CM con una edad media de 54 años. Las más prevalentes fueron periodontitis, gingivitis, úlceras, dolor, pérdida dental o xerostomía. Esta prevalencia se identificó más comúnmente en estudios de la vida real que en ensayos clínicos. La evidencia de carga humana y económica fue escasa y heterogénea, pero sugiere que las CO impactan negativamente en la calidad de vida y costos generales del tratamiento del CM. A pesar de que no son comúnmente estudiadas, las CO en pacientes con CM son numerosas e impactan negativamente en el tratamiento. La falta de investigación en salud oral estandarizada en la población oncológica representa un reto para el desarrollo de protocolos de atención oral personalizada de las sobrevivientes de CM.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Oral health]]></kwd>
<kwd lng="en"><![CDATA[Breast neoplasm]]></kwd>
<kwd lng="en"><![CDATA[Adverse events]]></kwd>
<kwd lng="en"><![CDATA[Epidemiology]]></kwd>
<kwd lng="en"><![CDATA[Quality of life]]></kwd>
<kwd lng="en"><![CDATA[Economics]]></kwd>
<kwd lng="es"><![CDATA[Salud oral]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
<kwd lng="es"><![CDATA[Eventos adversos]]></kwd>
<kwd lng="es"><![CDATA[Epidemiología]]></kwd>
<kwd lng="es"><![CDATA[Calidad de vida]]></kwd>
<kwd lng="es"><![CDATA[Economía]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Laversanne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2021</year>
<volume>71</volume>
<page-range>209-49</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taichman]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Havens]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Poznak CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2013</year>
<volume>137</volume>
<page-range>23-32</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sonis]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Elting]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Keefe]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Schubert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hauer-Jensen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectives on cancer therapy-induced mucosal injury:pathogenesis, measurement, epidemiology, and consequences for patients]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2004</year>
<volume>100</volume>
<numero>9 Suppl</numero>
<issue>9 Suppl</issue>
<page-range>1995-2025</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez-Espinosa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marroquín Velásquez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CO149 epidemiology and burden of oral complications following breast cancer treatment-a systematic literature review (PROSPERO CRD42021272130)-mucositis and stomatitis incidence from randomized trials]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2022</year>
<volume>25</volume>
<page-range>S47</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez-Espinosa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marroquin Velasquez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and burden of oral complications (OCs) following breast cancer treatment:a systematic literature review-risk factors for development of OCs]]></article-title>
<source><![CDATA[J Health Med Sci]]></source>
<year>2023</year>
<volume>9</volume>
<page-range>15-25</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Haverman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Stokman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Napenas]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Braber]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of dental disease management in cancer patients]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2018</year>
<volume>26</volume>
<page-range>155-74</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Napenas]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Hodgson]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Stokman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers-Stauffer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of dental disease in patients undergoing cancer therapy]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2010</year>
<volume>18</volume>
<page-range>1007-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Bensadoun]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roila]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of oral and gastrointestinal mucositis:ESMO clinical practice guidelines]]></article-title>
<collab>ESMO Guidelines Working Group</collab>
<source><![CDATA[Ann Oncol]]></source>
<year>2011</year>
<volume>22</volume>
<numero>Suppl 6</numero>
<issue>Suppl 6</issue>
<page-range>vi78-84</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JPT]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chandler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cumpston]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Handbook for Systematic Reviews of Interventions]]></source>
<year>2019</year>
<edition>2nd Edition</edition>
<publisher-loc><![CDATA[Chichester (UK) ]]></publisher-loc>
<publisher-name><![CDATA[John Wiley &amp;Sons]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Boutron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Mulrow]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The PRISMA 2020 statement:an updated guideline for reporting systematic reviews]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
<page-range>n71</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jardim]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Do Carmo Dos Santos Araujo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chiesa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Moraes]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Antoniazzi]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral health-related quality of life in breast cancer survivors]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2020</year>
<volume>28</volume>
<page-range>65-71</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willershausen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidtmann]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Azaripour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kledtke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Willershausen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hasenburg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between breast cancer chemotherapy, oral health and chronic dental infections:a pilot study]]></article-title>
<source><![CDATA[Odontology]]></source>
<year>2019</year>
<volume>107</volume>
<page-range>401-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taichman]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Poznak CH]]></given-names>
</name>
<name>
<surname><![CDATA[Inglehart]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses:a longitudinal analysis]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2016</year>
<volume>24</volume>
<page-range>4815-24</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Figueiredo de Souza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Parâmetros clínicos, periodontais, nutricionais e imaginológicos em pacientes em uso de inibidores de aromatase [dissertation]]></source>
<year>2022</year>
<page-range>188</page-range><publisher-name><![CDATA[Universidade Federal de Minas Gerais]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taichman]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Van Poznak]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Inglehart]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer:impact of different treatments]]></article-title>
<source><![CDATA[Spec Care Dentist]]></source>
<year>2018</year>
<volume>38</volume>
<page-range>36-45</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alaqeel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alnaim]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Abuzaid]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[AlSudairi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hiligsmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pcn473 preferences for chemotherapy side effects in Saudi breast cancer patients:a discrete-choice experiment]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2019</year>
<volume>22</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>S528-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morden]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Canney]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Velikova]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bartlett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19):a multicentre, phase 3, open-label, randomised, controlled trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2017</year>
<volume>18</volume>
<page-range>929-45</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fall-Dickson]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Mock]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Grimm]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gaston-Johansson]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stomatitis-related pain in women with breast cancer undergoing autologous hematopoietic stem cell transplant]]></article-title>
<source><![CDATA[Cancer Nurs]]></source>
<year>2008</year>
<volume>31</volume>
<page-range>452-61</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo-Fo-Wong]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[De]]></surname>
<given-names><![CDATA[Haes HC]]></given-names>
</name>
<name>
<surname><![CDATA[Aaronson]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Abbema DL]]></given-names>
</name>
<name>
<surname><![CDATA[Den]]></surname>
<given-names><![CDATA[Boer MD]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Hezewijk M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Don't forget the dentist:dental care use and needs of women with breast cancer]]></article-title>
<source><![CDATA[Breast]]></source>
<year>2016</year>
<volume>29</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nazari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Valcarcel]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Najafi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preferences of patients with HR+and HER2-breast cancer regarding hormonal and targeted therapies in the first line of their metastatic stage:a discrete choice experiment]]></article-title>
<source><![CDATA[Value Health Reg Issues]]></source>
<year>2021</year>
<volume>25</volume>
<page-range>7-14</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taichman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Griggs]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Inglehart]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Periodontal health, perceived oral health, and dental care utilization of breast cancer survivors]]></article-title>
<source><![CDATA[J Public Health Dent]]></source>
<year>2015</year>
<volume>75</volume>
<page-range>148-56</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taichman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Inglehart]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Giannobile]]></surname>
<given-names><![CDATA[WV]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kolenic]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Van Poznak]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Periodontal health in women with early-stage postmenopausal breast cancer newly on aromatase inhibitors:a pilot study]]></article-title>
<source><![CDATA[J Periodontol]]></source>
<year>2015</year>
<volume>86</volume>
<page-range>906-16</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hagiwara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shiroiwa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shimozuma]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kawahara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Uemura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer:results from the SELECT BC study]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2018</year>
<volume>36</volume>
<page-range>215-23</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbosa-Lima]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kameo]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Amorim]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Marinho]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast]]></article-title>
<source><![CDATA[Rev Ciênc Saúde]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>144-50</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diernberger]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Atter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bullen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events connected to breast cancer treatment and their associated decrease in quality-of-life scores]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2022</year>
<page-range>1-19</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marinho]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral Mucositis Due to Chemotherapy and Health-Related Quality of Life in Women with Breast Cancer]]></article-title>
<source><![CDATA[Ribeirão Preto:University of São Paulo]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prieto-Callejero]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fagundo-Rivera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Martin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Salgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2020</year>
<volume>99</volume>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tachi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Teramachi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Asano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Osawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kawashima]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermejo de Las Heras]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes Ramon]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Galve Calvo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[De la Haba Rodriguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Mata]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[Anton F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The economic burden of metastatic breast cancer in Spain]]></article-title>
<source><![CDATA[Eur J Hosp Pharm]]></source>
<year>2020</year>
<volume>27</volume>
<page-range>19-24</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dranitsaris]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kaura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer:a cost-utility analysis from a Chinese health care perspective]]></article-title>
<source><![CDATA[Clinicoecon Outcomes Res]]></source>
<year>2015</year>
<volume>7</volume>
<page-range>249-56</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Segui]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Oyaguez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Casado]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain]]></article-title>
<source><![CDATA[Clin Transl Oncol]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>692-700</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Masaquel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barnett]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse event-related costs for systemic metastatic breast cancer treatment among female medicaid beneficiaries]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2016</year>
<volume>19</volume>
<page-range>1027-33</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mittmann]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Koo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alloul]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Trudeau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer]]></article-title>
<source><![CDATA[Curr Oncol]]></source>
<year>2010</year>
<volume>17</volume>
<page-range>7-16</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rashid]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Baca]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Malecha]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Masaquel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system]]></article-title>
<source><![CDATA[Breast Cancer (Dove Med Press)]]></source>
<year>2016</year>
<volume>8</volume>
<page-range>173-81</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Yim]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cloutier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gauthier-Loiselle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gagnon-Sanschagrin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of costs associated with adverse events in patients with cancer]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bozza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fontanella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fanotto]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[De]]></surname>
<given-names><![CDATA[Carlo E]]></given-names>
</name>
<name>
<surname><![CDATA[Iacono]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bonotto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unplanned hospital admission of early breast cancer outpatients treated with adjuvant chemotherapy]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2015</year>
<volume>26</volume>
<numero>Supp 6</numero>
<issue>Supp 6</issue>
<page-range>6</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Araujo Sensever]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jardim]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrazzo]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Skupien]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Antoniazzi]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between tamoxifen and tooth loss in women with breast cancer]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2022</year>
<volume>30</volume>
<page-range>8193-9</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez-Jornet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Aznar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ceron]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Asta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salivary biomarkers in breast cancer:a cross-sectional study]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2021</year>
<volume>29</volume>
<page-range>889-96</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Mouridsen]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Reibel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brunner]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nauntofte]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction]]></article-title>
<source><![CDATA[Oral Oncol]]></source>
<year>2008</year>
<volume>44</volume>
<page-range>162-73</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsey]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Lalla]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Masaquel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kamath]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Brammer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens]]></article-title>
<source><![CDATA[Springerplus]]></source>
<year>2014</year>
<volume>3</volume>
<page-range>259</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elting]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costs of oral complications of cancer therapies:estimates and a blueprint for future study]]></article-title>
<source><![CDATA[J Natl Cancer Inst Monogr]]></source>
<year>2019</year>
<volume>2019</volume>
<page-range>lgz010</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
